Paul Giannasca
Plus aucun poste en cours
Profil
Paul Giannasca worked as a Scientist at OraVax, Inc. and as Vice President-Development at Acambis Plc and Genocea Biosciences, Inc. He obtained an undergraduate degree from Fairleigh Dickinson University and a doctorate degree from the University of Massachusetts.
Anciens postes connus de Paul Giannasca
| Sociétés | Poste | Fin |
|---|---|---|
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Corporate Officer/Principal | - |
Formation de Paul Giannasca
| Fairleigh Dickinson University | Undergraduate Degree |
| University of Massachusetts | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Acambis Plc
Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Health Technology |
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Health Technology |
